Cost-effectiveness analysis of pneumococcal conjugate vaccines, PCV21 vs PCV20, in adults aged  ≥60 years in Germany.

Simuzingili M, Mueller PP, Oexle LM, de Lepper M, Yi Z, Owusu-Edusei K

Open source

DOI
10.1080/14760584.2026.2739087
Published
2026 Dec
Container
Expert review of vaccines
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/14760584.2026.2739087,
  title = {Cost-effectiveness analysis of pneumococcal conjugate vaccines, PCV21 vs PCV20, in adults aged  ≥60 years in Germany.},
  author = {Simuzingili M and Mueller PP and Oexle LM and de Lepper M and Yi Z and Owusu-Edusei K},
  year = {2026},
  journal = {Expert review of vaccines},
  doi = {10.1080/14760584.2026.2739087},
  url = {https://doi.org/10.1080/14760584.2026.2739087}
}

RIS

TY  - JOUR
TI  - Cost-effectiveness analysis of pneumococcal conjugate vaccines, PCV21 vs PCV20, in adults aged  ≥60 years in Germany.
AU  - Simuzingili M
AU  - Mueller PP
AU  - Oexle LM
AU  - de Lepper M
AU  - Yi Z
AU  - Owusu-Edusei K
PY  - 2026
JO  - Expert review of vaccines
DO  - 10.1080/14760584.2026.2739087
UR  - https://doi.org/10.1080/14760584.2026.2739087
ER  - 

APA

M, S., PP, M., LM, O., M, D. L., Z, Y., & K, O. (2026). Cost-effectiveness analysis of pneumococcal conjugate vaccines, PCV21 vs PCV20, in adults aged  ≥60 years in Germany.. Expert review of vaccines. https://doi.org/10.1080/14760584.2026.2739087

Source records